


# PRODUCT INFORMATION



## AZD 2014

Item No. 17378

**CAS Registry No.:** 1009298-59-2  
**Formal Name:** 3-[2,4-bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide  
**Synonym:** Vistusertib  
**MF:** C<sub>25</sub>H<sub>30</sub>N<sub>6</sub>O<sub>3</sub>  
**FW:** 462.5  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 222, 277, 387 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

AZD 2014 is supplied as a crystalline solid. A stock solution may be made by dissolving the AZD 2014 in the solvent of choice, which should be purged with an inert gas. AZD 2014 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of AZD 2014 in these solvents is approximately 0.5, 1, and 10 mg/ml, respectively.

### Description

AZD 2014 is a potent, selective, ATP-competitive mTORC1/2 dual inhibitor that inhibits phosphorylation of both mTORC1 and 2 substrate proteins in whole cells.<sup>1</sup> It exhibits an IC<sub>50</sub> value of 2.81 nM against the isolated recombinant enzyme and >1,000-fold selectivity against all PI3K isoforms.<sup>1</sup> AZD 2014 has broad antiproliferative effects across multiple cell lines and reduces tumor growth in *in vivo* models of ER<sup>+</sup> breast cancer.<sup>1</sup> It has efficacy against acute myeloid leukemia when combined with the pan Pim kinase inhibitor AZD 1208 (Item No. 20235) and enhances the radiosensitivity of different cancer cell types.<sup>2-4</sup>

### References

1. Guichard, S.M., Curwen, K., Bihani, T., *et al.* AZD2014, an inhibitor of mTORC1 and mTORC2, is highly effective in ER<sup>+</sup> breast cancer when administered using intermittent or continuous schedules. *Mol. Cancer Ther.* **14(11)**, 2508-2518 (2015).
2. Harada, M., Benito, J., Yamamoto, S., *et al.* The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia *via* HSF pathway suppression. *Oncotarget* **6(35)**, 37930-37947 (2015).
3. Kahn, J., Hayman, T.J., Jamal, M., *et al.* The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. *Neuro. Oncol.* **16(1)**, 29-37 (2014).
4. Yu, C.-C., Huang, H.-b., Hung, S.-K., *et al.* AZD2014 radiosensitizes oral squamous cell carcinoma by inhibiting AKT/mTOR axis and inducing G<sub>1</sub>/G<sub>2</sub>/M cell cycle rrest. *PLoS One* **11(3)**, e0151942 (2016).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/09/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM